Photo taken from Susan Pandya/LinkedIn
Oct 31, 2023, 15:38
Susan Pandya: U.S. FDA approval of our targeted therapy underscores the efforts of our exceptional clinical research team
Susan Pandya, Vice President of Clinical Development and Global Head of Cancer Metabolism at Servier Pharmaceuticals, recently posted on LinkedIn.
“Today’s U.S. FDA approval of our targeted therapy in IDH1-mutated relapsed or refractory (R/R) myelodysplastic syndromes (MDS) underscores the efforts of our exceptional clinical research team, Servier Pharmaceuticals, in developing novel therapies for difficult and hard-to-treat cancers.
As the first and only approved targeted therapy for patients diagnosed with R/R MDS within this molecularly defined subset, this new indication reinforces the importance of mutational testing and its impact on improving patient outcomes.
View our full announcement here.”
Source: Susan Pandya/LinkedIn
News Feed
-
Dec 8, 2023, 17:10 | OpinionAaron Goodman: Let’s stop giving many cured young patients neuropathy
-
Dec 8, 2023, 16:29 | BlogBecome a SIOP member today or renew for 2024 membership year - SIOP
-
Dec 8, 2023, 15:51 | BlogSharon Kapambwe: Standing on the shoulders of giants- Professor Lynnette Denny
-
Dec 8, 2023, 12:47 | InsightTalha Badar: A few selected ALL abstracts to watch for at ASH23
-
Dec 9, 2023, 04:44President Biden: It's good for the millions of Americans who can't afford their medications
-
Dec 8, 2023, 17:40Ibrahim Halil Sahin: A common question I received after my tweet on the PEGASUS trial...
-
Dec 8, 2023, 17:32Daniel Stover: Tumor genomic testing (TGT) is standard for MBC patients
-
Dec 8, 2023, 12:47Talha Badar: A few selected ALL abstracts to watch for at ASH23
-
Dec 8, 2023, 12:40Amar Kelkar: We hope putting out independent cost-effectiveness analyses like this will encourage others to join
-
Dec 8, 2023, 16:33Big thank you to Dr. Rucha Kiran Patil for sharing their experiences and learnings on writing abstracts and poster presentations - Novo Nordisk Haemophilia Foundation
-
Dec 6, 2023, 14:57Tracy Gosselin: Jennifer Petruno Receives DAISY Award for Extraordinary Nurses
-
Dec 3, 2023, 16:34Tedros Adhanom Ghebreyesus: Grateful to Namibia’s Prime Minister Saara Kuugongelwa-Amadhila for her commitment to health
-
Dec 2, 2023, 18:08100 Influential Celebrities in Oncology: The 2023 Edition – Part 5
-
Dec 2, 2023, 16:50Mara Antonoff: When your famous friends come back to visit their humble beginnings
-
Dec 4, 2023, 16:26SIOP 2023 by Numbers! - International Society of Paediatric Oncology
-
Dec 2, 2023, 16:43In our recent survey, nearly 1,700 ASCO members shared feedback on the ABIM MOC requirements - ASCO
-
Nov 28, 2023, 17:34The International Association of Cancer Registries annual conference - IARC
-
Nov 26, 2023, 18:05Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
Nov 26, 2023, 17:58Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
Dec 8, 2023, 17:54Dana-Farber News congratulates Sara Tolaney on receiving the Susan G. Komen 2023 Rising Star Researcher Award
-
Dec 8, 2023, 17:35Timothy M. Pawlik: Excited to announce Samilia Obeng-Gyasi as THE inaugural Endowed Surgical Professor in Health Equity
-
Dec 7, 2023, 18:30Dinesh Pendharkar is appointed as an Adjunct Professor at Roswell Park Comprehensive Cancer Center
-
Dec 7, 2023, 04:37Karun Neupane: Dreams do come true. I am going to Moffitt Cancer Center to become a hematologist/oncologist!
-
Dec 6, 2023, 16:21Sandra L. Wong has been appointed the next Dean of Emory University School of Medicine and chief academic officer for Emory Healthcare - Emory School of Medicine